Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cohen syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Cohen syndrome. Displaying page 1 of 1.
    EudraCT Number: 2006-000860-10 Sponsor Protocol Number: 10729 Start Date*: 2006-06-30
    Sponsor Name:H. Lundbeck A/S
    Full Title: An Open-Label Study Investigating the Specific Effects of Memantine in Institutionalised Patients with Alzheimer’s Disease
    Medical condition: Effects of memantine treatment in institutionalised patients with Alzheimer's Disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-003475-20 Sponsor Protocol Number: S1543016 Start Date*: 2006-05-25
    Sponsor Name:Solvay Pharmaceuticals, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects with Psychosis and Behavioural Disturbances Associated wit...
    Medical condition: Dementia of the Alzheimer's type (DSM-IV TR) code 294.11
    Disease: Version SOC Term Classification Code Term Level
    10012271
    Population Age: Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001153-10 Sponsor Protocol Number: X4P-001-103 Start Date*: 2020-02-05
    Sponsor Name:X4 Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension
    Medical condition: WHIM Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010512 Congenital immunodeficiency LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) HU (Completed) ES (Ongoing) PL (Completed) AT (Completed) DE (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000504-41 Sponsor Protocol Number: 331-12-283 Start Date*: 2013-12-10
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Country-specific protocol amendment for Germany entitled: A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2...
    Medical condition: Agitation Associated with Dementia of the Alzheimer’s Type
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000503-17 Sponsor Protocol Number: 331-12-284 Start Date*: 2015-01-29
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC-34712) in the Treatme...
    Medical condition: Agitation Associated with Dementia of the Alzheimer’s Type
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Prematurely Ended) SI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-000862-14 Sponsor Protocol Number: A-bipolar Start Date*: 2021-07-08
    Sponsor Name:Copenhagen Affective Disorder research Center (CADIC),
    Full Title: Effects of low dose Aspirin in bipolar disorder – a randomized controlled trial (the A-Bipolar RCT)
    Medical condition: Bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10004935 Bipolar affective disorder, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004893-32 Sponsor Protocol Number: CL03-ORY-2001 Start Date*: 2018-04-03
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: A multicentre, multinational, randomised, double-blind, placebo-controlled, 3-arm, 24-week parallel-group study to evaluate the safety, tolerability and preliminary efficacy of ORY-2001 in patients...
    Medical condition: Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000798-26 Sponsor Protocol Number: 20-AVP-786-306 Start Date*: 2021-06-22
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q...
    Medical condition: Agitation in patients with dementia of the Alzheimer’s type
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001499 Agitation mental LLT
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) BG (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000799-39 Sponsor Protocol Number: 20-AVP-786-307 Start Date*: 2021-02-05
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q...
    Medical condition: Agitation in patients with dementia of the Alzheimer’s type
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001499 Agitation mental LLT
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) SK (Trial now transitioned) NL (Ongoing) SI (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001128-78 Sponsor Protocol Number: ACP-103-033 Start Date*: 2017-03-21
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer’s Disease
    Medical condition: Agitation and Aggression in Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005289-39 Sponsor Protocol Number: GER001-02-02 Start Date*: 2012-05-16
    Sponsor Name:Radboud university medical center
    Full Title: Efficacy and safety of delta-9-tetrahydrocannabinol (delta-THC) in behavioural disturbances and pain in dementia
    Medical condition: Subjects with mild to severe Alzheimer's dementia and/or vascular dementia with behavioural disturbances, with at least agitation, aggression or aberrant motor disturbances.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    16.1 10029205 - Nervous system disorders 10057678 Vascular dementia PT
    16.1 10018065 - General disorders and administration site conditions 10033371 Pain PT
    16.1 10029205 - Nervous system disorders 10012267 Dementia PT
    16.1 10037175 - Psychiatric disorders 10066842 Behavioural and psychiatric symptoms of dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001989-15 Sponsor Protocol Number: TV48125-MH-40142 Start Date*: 2020-03-27
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of...
    Medical condition: Migraine and major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027603 Migraine headaches HLT
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FR (Completed) FI (Completed) GR (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001674-34 Sponsor Protocol Number: AG348-C-020 Start Date*: 2022-02-17
    Sponsor Name:AGIOS PHARMACEUTICALS, INC.
    Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004583-26 Sponsor Protocol Number: LV2020-001 Start Date*: 2022-03-08
    Sponsor Name:LAVA Therapeutics N.V.
    Full Title: A Phase 1 and 2a open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory...
    Medical condition: Relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Prematurely Ended) ES (Completed) FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 11:50:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA